Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for screening and confirmation of cystic fibrosis. The tender with the University Hospital…
Devyser has been awarded a tender for Devyser RHD, its product for non-invasive fetal RHD status in maternal plasma during pregnancy. The tender with Wales Blood Services covers fetal RHD…
“Devyser is reporting record sales growth (+50% organic growth) for the third quarter, a further improvement in EBIT and continued high gross margins. Devyser’s transplant products were…
On Thursday November 9, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q3 2023 report (which will have been published earlier on November 9, at 07.30 CET).…
Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services. The goal is to partner with pharmaceutical companies to support their…
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including Brazil in the exclusive collaboration and distribution agreement for Devyser's…
“The second quarter of the year saw an improvement in EBIT compared with recent quarters, continued high gross margins, strong growth and an exclusive collaboration and distribution…
On Wednesday August 23, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q2 2023 report (which will have been published earlier on August 23, at 07.30 CET).…
Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted…
Devyser has inaugurated its CLIA-certified laboratory in Atlanta, Georgia. The laboratory will offer clinical test services for hereditary diseases, oncology, and post-transplant…
